AMGN - Amgen Inc
One of the original biotech pioneers, leveraging biologics expertise to build a portfolio in cardiovascular, oncology, and inflammation therapies.
Finlify Score
52.6 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$387.64
+0.00%
52W Range
$269.77 - $391.29
Market Cap
$195.4B
0.0%Compared to previous day
2026 Q1 Revenue
$8.6B
-12.6%Changes from last reporting quarter
2026 Q1 EPS
$3.34
Diluted shares
Analyst Rating
43 analysts in latest ratings feed
RSI
68.2
40-70 moderate
2Y Range Position
93%
-2.6% from high / +53.0% from low
Beta
0.42
Relative to market benchmark
MACD
1.90
MACD line 8.48 / signal line 6.58
Fundamental Trend
Growth 43.0Financial Health
Quality 80.8Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD52.6 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $8.6B-12.6% | $9.9B+3.2% | $9.6B+4.1% | $9.2B+12.6% |
| Gross Profit | - | - | - | - |
| Operating Income | $2.7B-2.0% | $2.7B+7.7% | $2.5B-4.9% | $2.7B+125.5% |
| Net Income | $1.8B+36.5% | $1.3B-58.6% | $3.2B+124.6% | $1.4B-17.2% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
Finlify's signal for AMGN is AVOID, with an overall Finlify Score of 45.9/100, suggesting potential concerns across several quantitative factors, particularly in accumulation and fundamental trends.
Technical
The Relative Strength score of 41.7/100 and a low Accumulation / Volume score of 12.7/100 appear to contribute to the AVOID signal. While the asset has shown positive 20-day (5.7%) and 60-day (9.2%) returns, its RSI of 61.0 suggests it is approaching overbought territory, and it remains -4.3% from its 52-week high.
Fundamentals
The Fundamental Trend score of 43.0/100 indicates some potential headwinds, despite a strong Financial Quality score of 80.8/100. Valuation metrics such as a P/E of 26.3x, P/B of 20.4x, and P/S of 5.5x may suggest the asset is trading at a premium. The asset also offers a dividend yield of 2.71% and exhibits a low Beta of 0.4, which could imply lower volatility.
Macro Context
The current macro environment, characterized by a 10Y Treasury Yield of 4.7% and a 2Y Treasury Yield of 4.3%, alongside a 3.7% CPI YoY, suggests a potentially higher interest rate and inflationary backdrop. Given AMGN's low Beta of 0.4, it may exhibit some resilience to broader market fluctuations, though the overall economic conditions could still influence growth prospects.
Key Risks
- The low Accumulation / Volume score of 12.7/100 may indicate limited buying interest or distribution.
- Valuation metrics such as a P/E of 26.3x and P/B of 20.4x appear elevated, potentially suggesting a premium valuation.
- Upcoming earnings on 2026-08-04 could introduce significant price volatility.